K Pharma,Inc.TSE: 4896

Financial Results Summary Q3 FY2026

· Issued by K Pharma,Inc. via TDnet

Filed with TSE · · 13 pages · English

Summary by 6ix AI

The report highlights an operating loss and increased research and development expenses, while no revenue was recorded during the period. The company has revised its full-year forecast, narrowing the expected operating loss compared to earlier estimates. Additionally, the report outlines progress in various clinical trials and business development activities related to its drug candidates.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

K Pharma,Inc. on 6ix

In the deck

Earlier from K Pharma,Inc

All K Pharma,Inc news releases